"I think that we're beginning to see the light at the end of the tunnel here," Eli Lilly CEO John Lechleiter tells WSJ regarding the payoff for what the Journal calls, a "relatively hefty R&D budget." Patent expirations for Zyprexa, Cymbalta, and Evista have hit revenue and the company is now betting on ramucirumab (in gastric cancer) and a once-a-day diabetes pill, as its R&D spend has ballooned to $5.3B, or 23% of revenue.
Help employers find you! Check out all the jobs and post your resume.
